Metabasis Therapeutics Announces Breakthrough in Liver-TARGETED Drug Delivery

Metabasis Therapeutics, Inc., a biopharmaceutical company focused on metabolic diseases linked to pathways in the liver, has made a significant breakthrough in liver-targeted drug delivery using its proprietary HepDirect technology. The company has published an article in The Journal of Pharmacology and Experimental Therapeutics, presenting evidence that HepDirect prodrugs can effectively target drugs to the liver and achieve more efficacious therapies for chronic liver diseases such as hepatitis B, hepatitis C, and primary liver cancer.

Key Takeaways:

The HepDirect technology represents a strategy for targeting drugs to the liver and achieving more efficacious therapies for chronic liver diseases.
The publication reports on preclinical results from studies of two of Metabasis' HepDirect prodrugs, pradefovir mesylate (MB06866) for hepatitis B, and MB07133 for primary liver cancer.
Both drug candidates are currently being clinically tested in patients, with preliminary evidence of efficacy demonstrated with CS-917 and pradefovir mesylate.
Metabasis has established a broad product pipeline targeting large markets with significant unmet medical needs, including type 2 diabetes, hepatitis B, and primary liver cancer.
The company has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic technology and the HepDirect technology.

Statistics:

Metabasis has established a broad product pipeline targeting large markets with significant unmet medical needs.
The company has three internally discovered, novel product candidates in clinical development: CS-917, pradefovir mesylate, and MB07133.
Preliminary evidence of efficacy has been demonstrated with CS-917 and pradefovir mesylate.
Metabasis has developed proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic technology and the HepDirect technology.

Sources:

Metabasis Therapeutics, Inc. (NASDAQ:MBRX)
The Journal of Pharmacology and Experimental Therapeutics
Health & Medicine Week editors
NewsRx.com & NewsRx.net